NCT06929936View on ClinicalTrials.gov

Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Non-Small Cell Lung CancerMyelosuppression
Interventions
DRUG

Trilaciclib combined with Docetaxel

"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to chemotherapy.~Docetaxel: 75mg/m2, iv. infusion for 1 hour on days 1 of each 21-day cycle, totaling 4 cycles of medication."

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER